Superpower peptides available for pre-order. Get first access.

Peptide science

How does PTD-DBM compare with minoxidil and finasteride?

No human study has compared PTD-DBM with minoxidil or finasteride. See how their targets, FDA status, and human trial evidence differ, with sources.

Quick answer

No human study has compared PTD-DBM with minoxidil or finasteride, so its effect relative to either drug in people is unknown. PTD-DBM has no registered human trial as of November 2026. The peptide itself has been tested only in mice and cells, and human data are limited to scalp tissue samples showing higher levels of its target, CXXC5. Minoxidil and finasteride are the only FDA-approved drugs for pattern hair loss. Both rest on randomized trials, including 1,553 men in the pivotal finasteride studies and 393 in a minoxidil trial.

Published
November 11, 2026
Last updated
November 11, 2026

PTD-DBM has never been compared with minoxidil or finasteride

No human study has compared PTD-DBM with minoxidil or finasteride, so how its effect on hair in people compares with either drug is unknown. PTD-DBM has no registered human trial1 as of November 2026, while minoxidil and finasteride are the only FDA-approved drugs for pattern hair loss2. Both approved drugs rest on randomized trials in people. The differences start with the biology each compound targets inside the hair follicle.

PTD-DBM vs minoxidil and finasteride: how each works

PTD-DBM, minoxidil, and finasteride each act on a different primary target in the hair follicle, so findings for one cannot stand in for the others.

Wnt signaling is a cell-to-cell messaging pathway central to hair follicle regeneration3. In mouse studies, Wnt signals help maintain the follicle's hair-inducing activity4. A protein called CXXC5 acts as a brake on Wnt in hair regeneration5 by binding a signaling protein called Dishevelled6. PTD-DBM is a peptide built to block that CXXC5 binding7, and it has been tested in mice.

Minoxidil works once hair follicles convert it into minoxidil sulfate, an active form identified in cultured mouse follicles8. How minoxidil sulfate promotes growth is not fully understood9. Proposed pathways include widened blood vessels and Wnt signaling10.

Finasteride blocks type II 5-alpha-reductase11, the enzyme that turns testosterone into dihydrotestosterone (DHT). Blocking that enzyme lowers DHT levels in scalp skin12.

CompoundPrimary targetFDA status for hair lossHuman randomized-trial evidence
PTD-DBMCXXC5 brake on Wnt signaling (in mice)Not FDA-approvedNo registered human trial as of November 2026
MinoxidilActive as minoxidil sulfate; not fully establishedTopical forms approved; 5% foam sold over the counter13; oral use off-label10Placebo-controlled minoxidil trials in men14 and in women with pattern hair loss15
FinasterideType II 5-alpha-reductase (DHT)Prescription drug, approved for men only11Placebo-controlled finasteride trials in men16

The three compounds have also reached very different stages of research.

PTD-DBM evidence is preclinical, unlike minoxidil and finasteride

PTD-DBM has been tested only in mice and cells, with human data limited to tissue observations of its target, while minoxidil and finasteride have been tested in placebo-controlled trials in people and pooled in meta-analyses.

In a 2017 mouse study, PTD-DBM sped hair regrowth and new follicle growth in skin wounds7. The same study found higher CXXC5 levels in balding human scalp tissue7, an observation from tissue samples with no treatment involved. A later mouse study from the same group17 found PTD-DBM restored hair lost to prostaglandin D2, a molecule tied to DHT-driven balding.

Finasteride's core evidence comes from two one-year trials in 1,553 men18, most of whom continued blinded into a second year. For minoxidil, a 48-week randomized trial in 393 men14 compared two strengths of the topical drug with placebo.

Pooled analyses of randomized trials found minoxidil and finasteride each superior to placebo19. A network meta-analysis later compared these drugs across 23 studies in men20. Evidence-based treatment guidelines for pattern hair loss in women and men21 draw on this body of trials. That difference in research maturity carries straight into decisions about thinning hair.

What PTD-DBM research means for thinning hair

PTD-DBM research cannot yet guide decisions about thinning hair. The starting point for any hair loss is a clinical evaluation. Dermatologists and other clinicians work out what is causing hair loss22, which matters because some types regrow on their own. Over-the-counter minoxidil foam is not meant for sudden or patchy loss23, or for hair loss with no known cause.

Hair growth supplements marketed for thinning hair raise the same evidence questions as PTD-DBM. No registered trial has examined PTD-DBM safety in people, which makes clear, well-sourced information about peptides especially useful.

Where can I learn about peptides?

Telling early peptide research apart from an approved hair loss drug starts with knowing where each finding came from. Superpower’s peptide library covers investigational peptides such as PTD-DBM. A team of health journalists and licensed clinicians writes and fact-checks every guide.

The science behind peptides explains how short chains of amino acids such as PTD-DBM are built, named, and studied.

IMPORTANT SAFETY INFORMATION

PTD-DBM is not approved by the FDA for any medical use. Research on this compound has been limited to laboratory and animal studies, and no human clinical trial has been registered as of November 2026. Its safety, appropriate dosing, and long-term effects in humans have not been established. PTD-DBM is not prescribed, compounded, or dispensed through Superpower. No study has compared PTD-DBM with minoxidil or finasteride, and PTD-DBM is not a substitute for an FDA-approved option for hair loss.

No human clinical safety data exist for PTD-DBM. Populations of particular theoretical concern based on its proposed mechanism include people with active or prior cancer, particularly Wnt-pathway-driven tumors, and people who are pregnant or breastfeeding, since Wnt signaling plays critical roles in embryonic development. Products sold online as PTD-DBM are unregulated and have not been tested for purity, identity, potency, or safety by any regulatory authority.

Finasteride is a prescription medication indicated for male pattern hair loss in men only and is not indicated for women. It is contraindicated in women who are or may potentially be pregnant because it may cause abnormalities of the external genitalia of a male fetus, and women who are or may be pregnant should not handle crushed or broken tablets. Reported adverse reactions include decreased libido, erectile dysfunction, and ejaculation disorder in clinical trials, and depression and suicidal ideation in postmarketing reports. Finasteride lowers serum PSA levels, and 5-alpha-reductase inhibitors may increase the risk of high-grade prostate cancer.

Minoxidil 5% topical foam is sold over the counter. The men's product label states it is for use by men only and is not for sudden or patchy hair loss, hair loss with no known cause, or anyone under 18. Ask a doctor before use if you have heart disease, and stop use and ask a doctor if chest pain, rapid heartbeat, faintness, or dizziness occurs. It may be harmful if used when pregnant or breastfeeding.

For questions about hair loss evaluation and evidence-based options, consult a licensed dermatologist or healthcare provider. Full FDA-approved prescribing information for finasteride and the drug facts label for minoxidil foam are available on DailyMed24.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to PTD-DBM. PTD-DBM is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science